Article
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
The New England journal of medicine - 1 Jun 2017
Bourlière Marc, Gordon Stuart C, Flamm Steven L, Cooper Curtis L, Ramji Alnoor, Tong Myron, Ravendhran Natarajan, Vierling John M, Tran Tram T, Pianko Stephen, Bansal Meena B, de Lédinghen Victor, Hyland Robert H, Stamm Luisa M, Dvory-Sobol Hadas, Svarovskaia Evguenia, Zhang Jie, Huang K C, Subramanian G Mani, Brainard Diana M, McHutchison John G, Verna Elizabeth C, Buggisch Peter, Landis Charles S, Younes Ziad H, Curry Michael P, Strasser Simone I, Schiff Eugene R, Reddy K Rajender, Manns Michael P, Kowdley Kris V, Zeuzem Stefan
Abstract excerpt
BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.